Atopic dermatitis (AD) is a chronic, pruritic immune-mediated inflammatory dermatosis
characterized by a T helper 2 (Th2) immune response phenotype and may be associated …

Background Individuals with psoriasis are at increased risk for psychiatric comorbidities,
including suicidal ideation and behavior (SIB). Objective To distinguish between the …

Background Interleukins 12 and 23 have important roles in the pathophysiology of psoriasis.
We assessed ustekinumab, a human monoclonal antibody directed against these cytokines …

Background Ustekinumab, a human monoclonal antibody against interleukins 12 and 23,
has shown therapeutic potential for psoriasis. This study assessed the efficacy and safety of …

Background Interleukin-17A is considered to be central to the pathogenesis of psoriasis. We
evaluated secukinumab, a fully human anti–interleukin-17A monoclonal antibody, in …

Psoriasis is a chronic disease, the severity of which varies among patients and changes
unpredictably over time in individual patients. Psoriasis can be exacerbated during …

Background In this phase 2, randomized, double-blind, placebo-controlled, dose-ranging
study, we assessed the efficacy and safety of brodalumab (AMG 827), a human anti …

Background Dupilumab (an anti-interleukin-4-receptor-α monoclonal antibody) blocks
signalling of interleukin 4 and interleukin 13, type 2/Th2 cytokines implicated in numerous …

Background Tumour necrosis factor α (TNFα) is thought to play a part in the pathogenesis of
psoriasis. We assessed the efficacy and safety of continuous treatment with infliximab, a …

Background Psoriasis has substantial psychological and emotional effects. We assessed the
effect of etanercept, an effective treatment for the clinical symptoms of psoriasis, on fatigue …